Retrospective Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Dec 26, 2021; 9(36): 11183-11192
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11183
Table 2 Patients’ characteristics dichotomized by clinically significant prostate cancer status

Non-csPca
csPCa
P value
Patients, n7156-
Age (yr), median (IQR)66 (62-70)70 (65-78)0.001
BMI (kg/m2), median (IQR)24.50 (23.05-26.70)24..75 (22.48-25.95)0.144
PSA (ng/mL), median (IQR)7.32 (5.16-11.69)8.88 (5.76-11.14)0.277
Proatate Volume (mL), median (IQR)41.02 (30.90-53.50)31.95 (23.39-39.65)0.001
PSAD (ng/mL/cm3), median (IQR)0.18 (0.13-0.26)0.30 (0.21-0.40)0.003
Largest dimention (cm), median(IQR)1.00 (0.60-1.30)1.10 (0.83-1.48)0.04
PI-RADS3 (3-5)4 (3-5)0.001
3, n (%)47 (66.20)10 (17.86)
4, n (%)19 (26.76)22 (39.29)
5, n (%)5 (7.04)24 (42.86)
Total cores, n (IQR)19 (17-22)18 (15-21)0.097